Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes.

Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA.

Mol Pharmacol. 2004 Dec;66(6):1679-89. Epub 2004 Sep 15.

2.

PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels.

Kohyama T, Liu X, Wen FQ, Zhu YK, Wang H, Kim HJ, Takizawa H, Cieslinski LB, Barnette MS, Rennard SI.

Am J Respir Cell Mol Biol. 2002 Jun;26(6):694-701.

PMID:
12034568
3.

Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.

Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, Torphy TJ, Barnette MS.

Br J Pharmacol. 1999 Dec;128(7):1393-8.

4.

Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation.

Baroja ML, Cieslinski LB, Torphy TJ, Wange RL, Madrenas J.

J Immunol. 1999 Feb 15;162(4):2016-23.

5.

1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.

Christensen SB, Guider A, Forster CJ, Gleason JG, Bender PE, Karpinski JM, DeWolf WE Jr, Barnette MS, Underwood DC, Griswold DE, Cieslinski LB, Burman M, Bochnowicz S, Osborn RR, Manning CD, Grous M, Hillegas LM, Bartus JO, Ryan MD, Eggleston DS, Haltiwanger RC, Torphy TJ.

J Med Chem. 1998 Mar 12;41(6):821-35.

PMID:
9526558
6.

Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.

Willette RN, Shiloh AO, Sauermelch CF, Sulpizio A, Michell MP, Cieslinski LB, Torphy TJ, Ohlstein EH.

J Cereb Blood Flow Metab. 1997 Feb;17(2):210-9.

PMID:
9040501
7.

Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding.

Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinski LB, Esser KM, Prabhakar US, Rush JA, Torphy TJ.

Biochem Pharmacol. 1996 Apr 12;51(7):949-56.

PMID:
8651945
8.

Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B.

Manning CD, McLaughlin MM, Livi GP, Cieslinski LB, Torphy TJ, Barnette MS.

J Pharmacol Exp Ther. 1996 Feb;276(2):810-8.

PMID:
8632354
9.
10.

Characterization of two human cAMP-specific phosphodiesterase subtypes expressed in baculovirus-infected insect cells.

Amegadzie BY, Hanning CR, McLaughlin MM, Burman M, Cieslinski LB, Livi GP, Torphy TJ.

Cell Biol Int. 1995 Jun;19(6):477-84.

PMID:
7640661
11.

The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.

Barnette MS, Manning CD, Cieslinski LB, Burman M, Christensen SB, Torphy TJ.

J Pharmacol Exp Ther. 1995 May;273(2):674-9.

PMID:
7752069
12.

A Candida albicans cyclic nucleotide phosphodiesterase: cloning and expression in Saccharomyces cerevisiae and biochemical characterization of the recombinant enzyme.

Hoyer LL, Cieslinski LB, McLaughlin MM, Torphy TJ, Shatzman AR, Livi GP.

Microbiology. 1994 Jul;140 ( Pt 7):1533-42.

PMID:
8075796
13.

The crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-(3-(cyclopentyloxy)- 4-methoxyphenyl)-pyrrolidin-2-one.

Baures PW, Eggleston DS, Erhard KF, Cieslinski LB, Torphy TJ, Christensen SB.

J Med Chem. 1993 Oct 29;36(22):3274-7.

PMID:
8230117
14.

Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle.

Torphy TJ, Undem BJ, Cieslinski LB, Luttmann MA, Reeves ML, Hay DW.

J Pharmacol Exp Ther. 1993 Jun;265(3):1213-23.

PMID:
8389856
16.
17.

Preliminary identification and role of phosphodiesterase isozymes in human basophils.

Peachell PT, Undem BJ, Schleimer RP, MacGlashan DW Jr, Lichtenstein LM, Cieslinski LB, Torphy TJ.

J Immunol. 1992 Apr 15;148(8):2503-10.

PMID:
1373172
18.

Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast.

Torphy TJ, Stadel JM, Burman M, Cieslinski LB, McLaughlin MM, White JR, Livi GP.

J Biol Chem. 1992 Jan 25;267(3):1798-804.

19.

Expression of human recombinant cAMP phosphodiesterase isozyme IV reverses growth arrest phenotypes in phosphodiesterase-deficient yeast.

McHale MM, Cieslinski LB, Eng WK, Johnson RK, Torphy TJ, Livi GP.

Mol Pharmacol. 1991 Feb;39(2):109-13.

PMID:
1847489
20.

Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase.

Livi GP, Kmetz P, McHale MM, Cieslinski LB, Sathe GM, Taylor DP, Davis RL, Torphy TJ, Balcarek JM.

Mol Cell Biol. 1990 Jun;10(6):2678-86.

21.
22.

Regulation of cAMP content and cAMP-dependent protein kinase activity in airway smooth muscle.

Torphy TJ, Burman M, Huang LB, Horohonich S, Cieslinski LB.

Prog Clin Biol Res. 1987;245:263-75. Review. No abstract available.

PMID:
2891141

Supplemental Content

Loading ...
Support Center